检索结果-南通市图书馆

家庭医学（上半月） 1996年第2期11卷 46-46页

作者：吴星

自1850年德国人赫尔曼·赫姆霍尔特斯医师发明第一部粗糙的检眼镜以来,瞳孔里面这个黑暗而神秘的世界变得光明了。检眼镜发出的光线进入瞳孔,所见眼底已放大16倍。看到的是一片淡橘黄色的薄膜,叫视网膜,它是脑的延伸。膜上有一个凹性... 详细信息

自1850年德国人赫尔曼·赫姆霍尔特斯医师发明第一部粗糙的检眼镜以来,瞳孔里面这个黑暗而神秘的世界变得光明了。检眼镜发出的光线进入瞳孔,所见眼底已放大16倍。看到的是一片淡橘黄色的薄膜,叫视网膜,它是脑的延伸。膜上有一个凹性亮点为黄斑的中心,由视锥细胞组成,是视物最主要的部位且司颜色的鉴别。黄斑周围由视杆细胞组成,主管黑暗时视物。黄斑病变可出现色盲、视力减退,见于视网膜炎等。

关键词：生命征象视网膜病变细胞组成视力减退检眼镜黄斑病变视神经乳头眼底高度近视三层膜

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

舒马曲坦鼻腔喷雾治疗青少年偏头痛的长时程耐受性

引用

世界核心医学期刊文摘（神经病学分册） 2005年第4期1卷 25-26页

作者： Natarajan S. Jabbour J.T. Webster C.J. Richardson M.S. 王英鹏 GlaxoSmithKline Research Triangle Park NC United States

Objective. - This 1- year, open- label, multicenter study was designed to assess the long- term tolerability and efficacy of sumatriptan nasal spray 20 mg in adolescent patients with migraine. Methods. - A prospective, multicenter, open- label study was conducted in patients aged 12 to 17 years who were allowed to treat an unlimited number of migraines at severe, moderate, or mild pain intensity with sumatriptan nasal spray for up to 1 year. All patients started the study at the 20- mg dose of sumatriptan nasal spray. Dose could be adjusted downward to 5 mg at the discretion of the investigator to optimize therapy. Results. - A total of 484 adolescent migraineurs treated 4676 migraines with sumatriptan nasal spray 20 mg (3593 during the first 6 months and 1083 during the second 6 months). A total of 3940 migraines and 699 migraines were treated with one and two 20- mg doses of sumatriptan nasal spray, respectively. Only 10 patients (treating 42 migraines) took the 5- mg dose of sumatriptan nasal spray. The overall percentage of migraines treated with either one 20- mg dose or one, two, or three 20- mg doses with at least 1 drug- related adverse event was 19% . The most common specific drug- related adverse event was unpleasant taste, reported in 17% of migraines. No other single drug- related adverse event was reported in more than 1% of migraines over the 1- year treatment period. When unpleasant taste was excluded from the adverse- event tabulations, the percentages of migraines with at least 1 drug- related adverse event after one or one, two, or three 20- mg doses declined to 4% and 3% , respectively. No patient experienced any drug- related changes in 12- lead ECGs, vital signs, or nasal assessments; and no clinically meaningful changes in clinical laboratory values were observed. Across all migraines with evaluable efficacy data (n = 4334), headache relief was reported in 43% of migraines at 1 hour and in 59% at 2 hours after dosing with sumatriptan nasal spra

关键词：头痛发作味觉感知舒马曲坦头痛程度功能评定生命征象数量限制

来源：

维普期刊数据库

同方期刊数据库评论